Total Payments
$768.39
2024 Payments
$276.78
Companies
17
Transactions
40
Medicare Patients
3,567
Medicare Billing
$505,846
Payment Breakdown by Category
Food & Beverage$708.45 (92.2%)
Education$59.94 (7.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $708.45 | 36 | 92.2% |
| Education | $59.94 | 4 | 7.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $133.80 | 7 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $106.31 | 6 | $0 (2024) |
| PFIZER INC. | $74.92 | 5 | $0 (2024) |
| Coherus Biosciences Inc. | $64.42 | 4 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $55.50 | 2 | $0 (2024) |
| Daiichi Sankyo Inc. | $45.57 | 2 | $0 (2024) |
| Janssen Biotech, Inc. | $42.00 | 2 | $0 (2022) |
| Pharmacyclics LLC, An AbbVie Company | $41.20 | 2 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $38.95 | 2 | $0 (2023) |
| Gilead Sciences, Inc. | $26.28 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $276.78 | 13 | Celgene Corporation ($59.98) |
| 2023 | $239.49 | 14 | Coherus Biosciences Inc. ($64.42) |
| 2022 | $142.62 | 7 | Janssen Biotech, Inc. ($42.00) |
| 2021 | $67.65 | 3 | Takeda Pharmaceuticals U.S.A., Inc. ($26.17) |
| 2018 | $30.95 | 2 | PFIZER INC. ($30.95) |
| 2017 | $10.90 | 1 | PFIZER INC. ($10.90) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/02/2024 | Merck Sharp & Dohme LLC | WELIREG (Drug) | Education | In-kind items and services | $18.09 | General |
| Category: ONCOLOGY | ||||||
| 11/11/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $27.90 | General |
| Category: Immunology | ||||||
| 10/21/2024 | E.R. Squibb & Sons, L.L.C. | KRAZATI (Drug) | Food and Beverage | Cash or cash equivalent | $24.39 | General |
| Category: Oncology | ||||||
| 10/14/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $17.89 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 09/09/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $24.54 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $15.18 | General |
| Category: ONCOLOGY | ||||||
| 06/03/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.31 | General |
| Category: Hematology | ||||||
| 05/13/2024 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $25.42 | General |
| Category: Hematology | ||||||
| 03/18/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $16.25 | General |
| Category: Hematology | ||||||
| 02/26/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $26.28 | General |
| 02/19/2024 | E.R. Squibb & Sons, L.L.C. | AUGTYRO (Drug) | Food and Beverage | Cash or cash equivalent | $13.90 | General |
| Category: Oncology | ||||||
| 01/22/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $27.60 | General |
| Category: Oncology | ||||||
| 11/22/2023 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 11/20/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $21.63 | General |
| 09/25/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.12 | General |
| Category: Oncology | ||||||
| 08/14/2023 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $18.98 | General |
| Category: Hematology | ||||||
| 05/22/2023 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 05/08/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $17.84 | General |
| Category: Hematology | ||||||
| 04/24/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: ONCOLOGY | ||||||
| 03/28/2023 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $16.01 | General |
| 03/21/2023 | Pharmacyclics LLC, An AbbVie Company | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: ONCOLOGY | ||||||
| 03/07/2023 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $16.14 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 02/07/2023 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $14.01 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 01/23/2023 | Celgene Corporation | Pomalyst (Drug) | Food and Beverage | Cash or cash equivalent | $16.37 | General |
| Category: Hematology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 679 | 1,721 | $302,117 | $163,728 |
| 2022 | 9 | 1,287 | 4,762 | $461,881 | $169,349 |
| 2021 | 11 | 1,146 | 3,502 | $337,347 | $120,965 |
| 2020 | 9 | 455 | 648 | $163,193 | $51,804 |
Total Patients
3,567
Total Services
10,633
Medicare Billing
$505,846
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 255 | 986 | $167,384 | $91,577 | 54.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 92 | 229 | $54,551 | $29,794 | 54.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 208 | 376 | $45,798 | $24,303 | 53.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 72 | 72 | $19,496 | $11,517 | 59.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 22 | 24 | $8,394 | $3,042 | 36.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $3,290 | $1,863 | 56.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 14 | 18 | $3,204 | $1,633 | 51.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 261 | 979 | $173,061 | $90,836 | 52.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 215 | 443 | $54,288 | $27,752 | 51.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 71 | 128 | $29,960 | $17,063 | 57.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2022 | 281 | 1,539 | $118,503 | $11,816 | 10.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 47 | 47 | $15,087 | $7,926 | 52.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 145 | 738 | $34,686 | $7,699 | 22.2% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 239 | 859 | $27,488 | $2,544 | 9.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 15 | 16 | $5,520 | $2,347 | 42.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 13 | 13 | $3,288 | $1,366 | 41.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 229 | 624 | $114,207 | $61,178 | 53.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 155 | 274 | $34,344 | $18,734 | 54.5% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 64 | 64 | $22,208 | $10,994 | 49.5% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2021 | 244 | 1,194 | $91,938 | $9,277 | 10.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 42 | 48 | $11,664 | $6,737 | 57.8% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2021 | 127 | 574 | $26,978 | $6,053 | 22.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 34 | 34 | $9,384 | $4,362 | 46.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 215 | 631 | $20,192 | $1,891 | 9.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 11 | 20 | $5,612 | $1,624 | 28.9% |
About Dr. Jeffrey Cronk, M.D
Dr. Jeffrey Cronk, M.D is a Hematology & Oncology healthcare provider based in Georgetown, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1811956220.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jeffrey Cronk, M.D has received a total of $768.39 in payments from pharmaceutical and medical device companies, with $276.78 received in 2024. These payments were reported across 40 transactions from 17 companies. The most common payment nature is "Food and Beverage" ($708.45).
As a Medicare-enrolled provider, Cronk has provided services to 3,567 Medicare beneficiaries, totaling 10,633 services with total Medicare billing of $505,846. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Georgetown, SC
- Active Since 03/23/2006
- Last Updated 11/21/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1811956220
Products in Payments
- REBLOZYL (Biological) $74.17
- Udenyca (Biological) $64.42
- Pomalyst (Drug) $59.63
- OPDIVO (Biological) $52.01
- Enhertu (Drug) $45.57
- IMBRUVICA (Drug) $41.20
- KRAZATI (Drug) $38.83
- Fabhalta (Drug) $27.90
- SCEMBLIX (Drug) $27.60
- NINLARO (Drug) $26.17
- DARZALEX (Biological) $22.33
- Nplate (Biological) $20.70
- VERZENIO (Drug) $20.49
- ZEPZELCA (Drug) $20.22
- MYLOTARG (Biological) $20.05
- LONSURF (Drug) $19.33
- WELIREG (Drug) $18.09
- BOSULIF (Drug) $17.89
- ENHERTU (Biological) $17.32
- ELREXFIO (Drug) $15.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Georgetown
Dr. David Milling, Md, MD
Hematology & Oncology — Payments: $7,588
Hematology & Oncology $7,588
Carol Bogdan, Md, MD
Hematology & Oncology — Payments: $5,059
Hematology & Oncology $5,059
Dr. Catherine Burbage, M.d, M.D
Hematology & Oncology — Payments: $3,860
Hematology & Oncology $3,860
Aabha Oza, M.d, M.D
Hematology & Oncology — Payments: $1,671
Hematology & Oncology $1,671
Dr. Courtney Yau, M.d, M.D
Hematology & Oncology — Payments: $1,474
Hematology & Oncology $1,474